NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $450.46 million. The enterprise value is $460.24 million.
Important Dates
The last earnings date was Tuesday, March 3, 2026, after market close.
| Earnings Date | Mar 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 33.67 million shares outstanding. The number of shares has increased by 12.35% in one year.
| Current Share Class | 33.67M |
| Shares Outstanding | 33.67M |
| Shares Change (YoY) | +12.35% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 3.76% |
| Owned by Institutions (%) | 67.47% |
| Float | 22.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.51 |
| Forward PS | 4.52 |
| PB Ratio | 23.61 |
| P/TBV Ratio | 23.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.28, with a Debt / Equity ratio of 3.72.
| Current Ratio | 5.28 |
| Quick Ratio | 4.25 |
| Debt / Equity | 3.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.19 |
Financial Efficiency
Return on equity (ROE) is -158.74% and return on invested capital (ROIC) is -11.93%.
| Return on Equity (ROE) | -158.74% |
| Return on Assets (ROA) | -10.20% |
| Return on Invested Capital (ROIC) | -11.93% |
| Return on Capital Employed (ROCE) | -18.62% |
| Weighted Average Cost of Capital (WACC) | 13.67% |
| Revenue Per Employee | $478,402 |
| Profits Per Employee | -$102,703 |
| Employee Count | 209 |
| Asset Turnover | 1.00 |
| Inventory Turnover | 1.50 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.31% in the last 52 weeks. The beta is 1.87, so NeuroPace's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | +11.31% |
| 50-Day Moving Average | 15.08 |
| 200-Day Moving Average | 12.44 |
| Relative Strength Index (RSI) | 39.10 |
| Average Volume (20 Days) | 240,642 |
Short Selling Information
The latest short interest is 805,229, so 2.39% of the outstanding shares have been sold short.
| Short Interest | 805,229 |
| Short Previous Month | 869,265 |
| Short % of Shares Out | 2.39% |
| Short % of Float | 3.52% |
| Short Ratio (days to cover) | 5.14 |
Income Statement
In the last 12 months, NeuroPace had revenue of $99.99 million and -$21.47 million in losses. Loss per share was -$0.66.
| Revenue | 99.99M |
| Gross Profit | 77.22M |
| Operating Income | -16.34M |
| Pretax Income | -21.47M |
| Net Income | -21.47M |
| EBITDA | -16.10M |
| EBIT | -16.34M |
| Loss Per Share | -$0.66 |
Full Income StatementBalance Sheet
The company has $61.06 million in cash and $70.84 million in debt, with a net cash position of -$9.78 million or -$0.29 per share.
| Cash & Cash Equivalents | 61.06M |
| Total Debt | 70.84M |
| Net Cash | -9.78M |
| Net Cash Per Share | -$0.29 |
| Equity (Book Value) | 19.03M |
| Book Value Per Share | 0.57 |
| Working Capital | 76.26M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.01 million and capital expenditures -$332,000, giving a free cash flow of -$11.34 million.
| Operating Cash Flow | -11.01M |
| Capital Expenditures | -332,000 |
| Depreciation & Amortization | 238,000 |
| Net Borrowing | -2.07M |
| Free Cash Flow | -11.34M |
| FCF Per Share | -$0.34 |
Full Cash Flow StatementMargins
Gross margin is 77.23%, with operating and profit margins of -16.34% and -21.47%.
| Gross Margin | 77.23% |
| Operating Margin | -16.34% |
| Pretax Margin | -21.47% |
| Profit Margin | -21.47% |
| EBITDA Margin | -16.10% |
| EBIT Margin | -16.34% |
| FCF Margin | n/a |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.35% |
| Shareholder Yield | -12.35% |
| Earnings Yield | -4.77% |
| FCF Yield | -2.52% |
Analyst Forecast
The average price target for NeuroPace is $18.33, which is 37.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.33 |
| Price Target Difference | 37.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 16.84% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -3.33 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.33 |
| Piotroski F-Score | 4 |
